Rockfish Bio
Pre-clinicalRockfish Bio, a spin-off of BOKU and Medical University of Vienna, convinced the jury with its novel senolytic drug candidates, which specifically target and remove senescent cells — aged, dysfunctional cells that accumulate in tissues over time and contribute to chronic diseases. By leveraging a specific metabolic pathway found in these aged cells, Rockfish Bio's compounds eliminate them without harming healthy cells.
About
Rockfish Bio, a spin-off of BOKU and Medical University of Vienna, convinced the jury with its novel senolytic drug candidates, which specifically target and remove senescent cells — aged, dysfunctional cells that accumulate in tissues over time and contribute to chronic diseases. By leveraging a specific metabolic pathway found in these aged cells, Rockfish Bio's compounds eliminate them without harming healthy cells.
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile